Tislelizumab for cervical cancer: A retrospective study and analysis of correlative blood biomarkers.

Xiaojing Zheng,Haifeng Gu,Xinping Cao,Baoyue Pan,Huiling Xiang,Mingxiu Ju,Shijie Xu,Min Zheng

Frontiers in immunology（2023）

引用 3|浏览15

暂无评分

摘要

Tislelizumab showed promising antitumor activity and tolerable toxicity in patients with R/M CC. The baseline serum CRP levels and CAR showed potential for predicting the efficacy of tislelizumab and the prognosis of R/M CC patients receiving tislelizumab.

查看译文

关键词

CAR,CRP,adverse events,cervical cancer,efficacy,prognosis,tislelizumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要